Mammography World Markets

5. Mammography: An Overview 66

5.1 Screen-Film Mammography 66

5.2 2D Digital Mammography 67

5.3 3D Digital Mammography 68

5.3.1 Better Visualization in 3D Images 70

5.3.1.1 3D Imaging and Superimposed Breast Tissue 71

5.3.1.2 Status of Tomosynthesis 72

5.3.1.3 Other Companies Working on Digital Breast Tomosynthesis (DBT) 73

5.3.1.4 Features of Hologic Tomosynthesis Unit 73

5.3.1.5 GE Tomosynthesis 73

5.3.1.6 Siemens Tomosynthesis 73

5.3.1.7 Philips (Sectra) Tomosynthesis 73

5.3.2 Difference between 3D and 2D Digital Mammography 74

5.3.2.1 Comparative Merits of Digital and Film-Screen Mammography 74

5.4 Basic Physics of Mammography 75

5.4.1 Mammography X-Ray Tubes 75

5.4.2 Mammography Image Receptors 77

5.4.3 Mammography AEC 79

5.4.4 Mammography Scatter Reduction 79

5.4.5 Differences in Dose Levels among Digital Mammography Systems 79

5.4.6 The Irish Study 79

5.4.7 Patient Radiation Doses in Swedish Screening Program 80

5.5 Points to be Considered Before Buying a Mammography System 81

5.6 Cost Containment in Mammography Systems 82

6. Screening Mammography Data from Selected Countries 846.1 U.S. Data on Screening Mammography 846.1.1 Prevalence of Mammography in the U.S. 846.1.2 Drop in U.S. Mammography Rates 846.1.3 Guidelines for Screening Mammography in the U.S. 856.1.4 Crisis in U.S. Mammography Services 856.1.5 Current Mammography Use in the U.S. 876.2 Organized Screening Programs in Canada 896.2.1 Early Detection of Breast Cancer in Canada 896.2.2 Distribution of Breast Cancer Detected during Screening by Stage in Canada 916.2.3 Newly Diagnosed Women with Her2+ by Province in Canada 916.2.4 Breast Cancer Treatment after Diagnosis in Canada 926.2.5 Radiation Therapy after Diagnosis in Canada 936.2.6 Chemotherapy after Breast Cancer Screening in Canada 936.2.7 Screening Mammography in British Colombia (BC) 946.2.7.1 Annual Screening Volume in BC 946.2.7.2 Bilateral Mammography Utilization in BC 966.2.7.3 Histologic Features of Breast Cancers Detected by SMP in BC 966.3 European Data on Screening Mammography 966.3.1 Screening Mammography Rates in OECD Countries 1006.3.2 Screening Mammography in the U.K. 1026.3.3 Screening Activity in the U.K. 1026.3.4 Acceptance of Screening Invitation by Age—All Invitation Types in the U.K. 1026.3.5 Acceptance by Type of Screen in the U.K. 1036.3.6 Screening Quality—First Screen after First Invitation in the U.K. 1036.3.7 Screening Quality—Subsequent Screening in the U.K. 1036.3.8 Screening—Women Aged 71 and Over in the U.K. 1046.3.9 Assessment Outcomes—Age 50-70 in the U.K. 1046.3.10 Assessment Outcomes—Age 45-74 in the U.K. 1056.3.11 Treatment of Screen Detected Breast Cancer in the U.K. 1056.3.12 Immediate Reconstruction after Mastectomy in the U.K. 1066.4 Screening Mammography in Korea 1076.5 Screening Mammography in Japan 1076.6 National Mammography Screening Program in Israel, 2010 1086.7 Mammography in Australia 1096.7.1 MBS-Funded Mammography in 2011 1106.7.2 Differences in Mammography Services by Age in Australia 1116.7.3 Hospitalizations for Female Breast Cancer in Australia 1116.7.4 Most Commonly Undertaken Female Breast Cancer Procedures in Australia 112

7. Mammography: Market Analysis 113

« First ‹ Previous 1 2 3 4 5 6 7 8 9 ... Next › Last »